Related Experiment Video
Updated: Feb 9, 2026

Author Spotlight: Advancements in Multiplex Detection of Respiratory Viruses
Published on: November 10, 2023
Prophylactic and therapeutic efficacy of mAb treatment against MERS-CoV in common marmosets
Emmie de Wit1, Friederike Feldmann2, Atsushi Okumura3
1Laboratory of Virology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, USA.
Abstract:
The high case-fatality rate of confirmed MERS-CoV infections underlines the urgent need for an effective treatment to reduce the disease severity and mortality. REGN3051 and REGN3048 are two fully human neutralizing monoclonal antibodies (mAb) against MERS-CoV that reduced virus replication in mice expressing human DPP4 upon prophylactic and therapeutic treatment. Here, we evaluated the prophylactic and therapeutic efficacy of REGN3048 and REGN3051 in the common marmoset model of MERS-CoV infection. Intravenous administration of mAb resulted in high levels of MERS-CoV-neutralizing activity in circulating blood. When animals were treated with mAbs one day before challenge, respiratory disease was less severe and, in animals treated with both REGN3048 and REGN3051, viral loads in the lungs were reduced. However, therapeutic treatment on day one after challenge was less efficacious as it did not prevent the development of severe respiratory disease and all treated animals developed bronchointerstitial pneumonia of similar severity as the control animals. Thus, mAb administration may be more effective in a prophylactic treatment regimen rather than treatment of MERS.
Insights
Two neutralizing monoclonal antibodies (mAbs) showed prophylactic efficacy against Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in marmosets. Therapeutic treatment was less effective, suggesting mAbs are best for preventing MERS-CoV infection.
Area of Science:
- Virology
- Immunology
- Infectious Diseases
Background:
- Middle East Respiratory Syndrome Coronavirus (MERS-CoV) has a high case-fatality rate, necessitating effective treatments.
- Neutralizing monoclonal antibodies (mAbs) REGN3051 and REGN3048 have shown promise against MERS-CoV in preclinical models.
Purpose of the Study:
- To evaluate the prophylactic and therapeutic efficacy of REGN3048 and REGN3051 in a common marmoset model of MERS-CoV infection.
Main Methods:
- Common marmosets were treated intravenously with REGN3048 and/or REGN3051 either one day before or one day after MERS-CoV challenge.
- Efficacy was assessed by measuring MERS-CoV-neutralizing activity in blood, respiratory disease severity, and viral loads in the lungs.
Main Results:
- Prophylactic treatment with mAbs one day before challenge reduced respiratory disease severity and viral lung loads when both antibodies were used.
- Therapeutic treatment one day after challenge was less effective, with all treated animals developing severe bronchointerstitial pneumonia.
Conclusions:
- Monoclonal antibody administration may be more effective as a prophylactic measure against MERS-CoV rather than a therapeutic intervention after infection.
- Further research into the optimal timing and combination of mAbs for MERS-CoV treatment is warranted.
Related Concept Videos
Common Ion Effect
Self-Efficacy
Therapeutic Index
Common Respiratory Disorders
Upper respiratory disorders impact the airways above the vocal cords, encompassing areas like the nose, sinuses, and throat. Various conditions fall under this category, including the common cold and allergic rhinitis. These disorders can stem from several causes,...
Mass Analyzers: Common Types
Common Leveling Mistakes and Errors

